Tumor-stromal interactions in breast tumor progression-significance of histological heterogeneity of tumor-stromal fibroblasts

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 4, 2013, Pages 449-460

  Hasebe, Takahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Breast; Carcinoma; Endothelial cell; Fibroblast; Fibrotic focus

Indexed keywords

COLLAGEN FIBER;

ANGIOGENESIS; BREAST CARCINOMA; BREAST TUMOR; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; ENDOTHELIUM CELL; FIBROBLAST; FIBROTIC FOCUS; HISTOPATHOLOGY; HUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIMARY TUMOR; REVIEW; STROMA; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR STROMAL FIBROBLAST;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL COMMUNICATION; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; STROMAL CELLS;

EID: 84875180001     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.757305     Document Type: Review

References (103)

1. Aye MM, Ma C, Lin H, et al. Ethanol-induced in vitro invasion of breast cancer cells: The contribution of MMP-2 by fibroblasts. Int J Cancer 2004;112:738-46
2. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48
3. Cheng N, Bhowmick NA, Chytil A, et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 2005;24:5053-68
4. Fiegl H, Millinger S, Goebel G, et al. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: Association with HER-2/neu status in primary breast cancer. Cancer Res 2006;66:29-33
5. Studebaker AW, Storci G, Werbeck JL, et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an Interleukin-6-dependent manner. Cancer Res 2008;68:9087-95
6. Jedeszko C, Victor BC, Podgorski I, et al. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res 2009;69:9148-55
7. Camp JT, Elloumi F, Roman-Perez E, et al. Interactions with fibroblasts are distinct in basal-like and luminal breast cancers. Mol Cancer Res 2010;9:3-13
8. Desmedt C, Jajjaj S, Kheddoumi N, et al. Characterization and clinical evaluation of CD10+ stroma Cells in the breast cancer microenvironment. Clin Cancer Res 2012;18(4):1004-14
9. Simpkins SA, Hanby AM, Holliday DL, Speirs V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol 2012;227:490-8
10. Tsuyada A, Chow A, Wu J, et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 2012;72:2768-79
11. Jung EJ, Moon HG, Cho BI, et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007;120:2331-8
12. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-25
13. Singer CF, Gschwantler-Kaulich D, Fink-Retter A, et al. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat 2008;110:273-81
14. True LD, Zhang H, Ye M, et al. CD90/THY1 is overexpressed in prostate cancer- associated fibroblasts and could serve as a cancer biomarker. Mod Pathol 2010;23:1346-56
15. Enkelmann A, Heinzelmann J, von Eggeling F, et al. Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. J Cancer Res Clin Oncol 2011;137:751-9
16. Li Q, Wang W, Yamada T, Matsumoto K. Pleural mesothelioma instigates tumor- associated fibroblasts to promote progression via a malignant cytokine network. Am J Pathol 2011;179:1483-93
17. Fuyuhiro Y, Yashiro M, Noda S, et al. Upregulation of cancer-associated myofibroblasts by TGF-beta from scirrhous gastric carcinoma cells. Br J Cancer 2011;105:996-1001
18. Comito G, Giannoni E, Di Gennaro P, et al. Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness. Cancer Lett 2012;324:31-41
19. Schoppmann SF, Berghoff A, Dinhof C, et al. Podplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat 2012;134:237-44
20. Acs G, Esposito NN, Kiluk J, et al. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX recurrence scores in low-grade invasive breast carcinomas. Mod Pathol 2012;25:556-66
21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-l0
22. Sobin LH, Gospodarowicz MK, Wittekind Ch. International Union Against Cancer. TNM classification of malignant tumours. In: Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. 7th edition. Wiley-Liss, Geneva; 2009. p. 181-193
23. Linell F, Ljungberg O, Andersson I. Breast carcinoma. Aspects of early stages, progression, and related problems. Acta Pathol Microbiol Scand 1980(Suppl 272):1-233
24. Fisher ER, Palekar AS, Sass R, Fisher B. Scar cancers: Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4) - IX. Breast Cancer Res Treat 1983;3:39-59
25. Toikkanen S, Joensuu H. Long-term prognosis of scar and non-scar cancers of the breast. APMIS 1990;98:1033-8
26. Partanen S, Hyvarinen H. Scar and non-scar ductal cancer of the female breast. Observations on patient age, tumour size, and hormone receptors. Virchows Arch (A) Pathol Anat 1987;412:145-9
27. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in invasive ductal carcinoma: An indicator of high tumor aggressiveness. Jpn J Cancer Res 1996;87:385-94
28. Hasebe T, Tsuda H, Tsubono Y, et al. Fibrotic focus in invasive ductal carcinoma: A histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation. Jpn J Cancer Res 1997;88:590-9
29. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: A significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 1998;49:195-208
30. Hasebe T, Sasaki S, Imoto S, et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: A prospective observational study. Mod Pathol 2002;15:502-16
31. Hasebe T, Imoto S, Yokose T, et al. Histopathologic factors significantly associated with initial organ-specific metastasis by invasive ductal carcinoma of the breast: A prospective study. Hum Pathol 2008;39:681-93
32. Colpaert C, Vermeulen P, van Beest P, et al. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 2001;39:416-25
33. Baak JPA, Colpaert C, van Diest PJ, et al. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer 2005;41:2093-101
34. Colpaert C, Vermeulen PB, Jeuris W, et al. Early distant relapse in "nodenegative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol 2001;193:442-9
35. Colpaert CG, Vermeulen PB, Fox SB, et al. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat 2003;81:137-47
36. Tamura N, Hasebe T, Okada N, et al. Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy. Cancer Sci 2009;100:1823-33
37. Maiorano E, Regan MM, Viale G, et al. Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat 2010;121:211-18
38. Kornegoor R, Verschuur-Maes AH, Buerger H, et al. Fibrotic focus and hypoxia in male breast cancer. Mod Pathol 2012;25:1397-404
39. Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: A review of morphology and immunophenotypical analysis. Mod Pathol 2005;18:26-35
40. Tsuda H, Takarabe T, Hasegawa T, et al. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999;30:1134-9
41. Tsuda H, Takarabe T, Hasegawa F, et al. Large, central acellular zones indicating myoepithelial tumor differentiation in highgrade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000;24:197-202
42. Jitsuiki Y, Hasebe T, Tsuda H, et al. Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast. Mod Pathol 1999;12:492-8
43. Van den Eynden GG, Smid M, Van Laere SJ, et al. Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer. Clin Cancer Res 2008;14:2944-52
44. Hasebe T, Sasaki S, Imoto S, et al. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol 2000;156:1701-10
45. Kurose K, Gilley S, Matsumoto PH, et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinoma. Nat Genet 2002;32:355-7
46. Hill R, Song Y, Cardiff RD, et al. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2006;123:1001-11
47. Bierie B and Moses HL. Under pressure: Stromal fibroblasts change their ways. Cell 2005;123:985-7
48. Moinfar F, Man YG, Arnould L, et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: Implication for tumorigenesis. Cancer Res 2000;60:2562-6
49. Patocs A, Zhang Li, Xu Y, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007;357:2543-51
50. Hasebe T, Okada N. Tamura N, et al. p53 expression in tumor-stromal fibroblasts is closely associated with the outcome of patients with invasive ductal carcinoma. Cancer Sci 2009;100:2101-8
51. Hasebe T, Tamura N, Okada N, et al. p53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy. Hum Pathol 2010;41:262-70
52. Hasebe T, Iwasaki M, Akashi-Tanaka S, et al. p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci in invasive ductal carcinoma of the breast. Mod Pathol 2010;23:662-72
53. Hasebe T, Imoto S, Ogura T, Mukai K. Significance of basic fibroblast growth factor and fibroblast growth factor receptor protein expression in the formation of fibrotic focus in invasive ductal carcinoma of the breast. Jpn J Cancer Res 1997;88:877-85
54. Van den Eynden GG, Colpaert CG, Couvelard A, et al. A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: Review of the literature and proposal on the criteria of evaluation. Histopathololgy 2007;51:440-51
55. Saito RA, Micke P, Paulsson J, et al. Forkhead Box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res 2010;70:2644-54
56. Tsujino T, Seshimo I, Yamamoto H, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res 2007;13:2082-90
57. Zhang C, Fu J, Hu L, et al. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res 2009;15:4017-27
58. Hasebe T, Iwasaki M, Akashi-Tanaka S, et al. Atypical tumor-stromal fibroblasts in invasive ductal carcinoma of the breast. Am J Surg Pathol 2011;35:325-36
59. Hasebe T, Iwasaki M, Akashi-Tanaka S, et al. Important histologic outcome predictors for patients with invasive ductal carcinoma of the breast. Am J Surg Pathol 2011;35:1484-97
60. Hasebe T, Yamauchi C, Iwasaki M, et al. Grading system for lymph vessel tumor emboli for prediction of the outcome of invasive ductal carcinoma of the breast. Hum Pathol 2008;39:427-36
61. Hasebe T, Okada N, Iwasaki M, et al. Grading system for lymph vessel tumor emboli: Significant outcome predictor for invasive ductal carcinoma of the breast. Hum Pathol 2010;41:706-15
62. Hasebe T, Sasaki S, Imoto S, Ochiai A. Significance of nodal metastatic tumor characteristics in nodal metastasis and prognosis of patients with invasive ductal carcinoma of the breast. Cancer Sci 2003;94:181-7
63. Hasebe T, Iwasaki M, Akashi-Tanaka S, et al. Prognostic significance of mitotic figures in metastatic mammary ductal carcinoma to the lymph nodes. Hum Pathol 2011;42:1823-32
64. Hasebe T, Sasaki S, Imoto S, Ochiai A. Histological characteristics of tumors in vessels and lymph nodes are significant parameter for predicting tumor progression of invasive ductal carcinoma of the breast: A prospective study. Hum Pathol 2004;35:298-308
65. Sobin LH, Wittekind CH. TNM classification of malignant tumors. 6th edition. Wiley-Liss, New York (NY); 2002. p. 131-141
66. Todd JH, Dowle C, Williams MR, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987;56:489-92
67. Sundquist M, Thorstenson S, Brudin L, et al. Applying the nottingham prognostic index to a Swedish breast cancer population. Breast Cancer Res Treat 1999;53:1-8
68. Hasebe T, Sasaki S, Imoto S, et al. Primary tumor-vessel tumor-nodal tumor classification for patients with invasive ductal carcinoma of the breast. Br J Cancer 2005;592:847-56
69. Blamey RW, Ellis IO, Pinder SE, et al. Survival of invasive breast cancer according to the nottingham prognostic index in cases diagnosed in 1990-1999. Eur J Cancer 2007;43:1548-55
70. Hasebe T, Iwasaki M, Akashi-Tanaka S, et al. Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast. Br J Cancer 2011;105:698-708
71. Markopoulos C, Xepapadakis G, Venizelos V, et al. Clinical experience of using oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions. Eur J Surg Oncol 2012;38:413-19
72. Kondo M, Hoshi SL, Ishiguro H, Toi M. Economic evaluation of the 70-gene prognosis- signature (MammaPrint-) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan. Breast Cancer Res Treat 2012;133:759-68
73. Gullotti L, Czerwitzki J, Kirfel J, et al. FHL2 expression in peritumoural fibroblasts correlates with lymphatic metastasis in sporadic but not in HNPCC-associated colon cancer. Lab Invest 2011;91:1695-705
74. Henriksson ML, Edin S, Dahlin AM, et al. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. Am J Pathol 2011;178:1387-94
75. Nishihara Y, Aishima S, Hayashi A, et al. CD10+ fibroblasts are more involved in the progression of hilar/extrahepatic cholangiocarcinoma than of peripheral intrahepatic cholangiocarcinoma. Histopathology 2009;55:423-31
76. Arnes JB, Stefansson IM, Straume O, et al. Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Res Treat 2012;133:501-10
77. Nishimura R, Hasebe T, Tsubono Y, et al. The fibrotic focus in advanced colorectal carcinoma: A hitherto unrecognized histological predictor for liver metastasis. Virchows Arch 1998;433:517-22
78. Hasebe T, Morihiro M, Sasaki S, et al. Tumor thickness is a histopathologic predictive parameter of tumor metastasis and prognosis in patients with Dukes stage C ulcerative- type colorectal carcinoma. A two-hospital-based study. Cancer 2000;89:35-45
79. Hasebe T, Sasaki S, Sugitoh M, et al. Proliferative activities of tumor stromal cells play important roles in tumor thickness and progression of T3 ulcerative-type colorectal cancer. Virchows Arch 2003;442:569-76
80. Hasebe T, Sasaki S, Sugitoh M, et al. Highly proliferative intratumoral fibroblasts and a high proliferative microvessel index are significant predictors of tumor metastasis in T3 ulcerative-type colorectal cancer. Hum Pathol 2001;32:401-9
81. Hasebe T, Konishi M, Iwasaki M, et al. Histological characteristics of tumor cells and stromal cells in vessels and lymph nodes are important prognostic parameters of extrahepatic bile duct carcinoma: A prospective study. Hum Pathol 2005;36:655-64
82. Hasebe T, Konishi M, Iwasaki M, et al. Primary tumor/vessel tumor/nodal tumor classification of extrahepatic bile duct carcinoma. Hum Pathol 2008;39:37-48
83. Sun W, Sohal D, Haller DG, et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 2011;117:3187-92
84. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96
85. Demetri GD, Garrett CR, Schoffski P, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012;18:3170-9
86. Piperdi B, Walsh WV, Bradley K, et al. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non- small-cell lung cancer. J Thorac Oncol 2012;7:1032-40
87. Reardon DA, Conrad CA, Cloughesy T, et al. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol 2012;69:1507-18
88. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Eng J Med 2007;357:2666-76
89. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47
90. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo- controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60
91. Couvelard A, O'Toole D, Leek R, et al. Expression of hypoxiainducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 2005;46:668-76
92. Couvelard A, O'Toole D, Turley H, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: Negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005;92:94-101
93. Burdelya LG, Komarova EA, Hill JE, et al. Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res 2006;66:9356-61
94. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006;116:1955-62
95. Amin DN, Hida K, Bielenberg DR, Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR Kinase inhibitors. Cancer Res 2006;66:2173-80
96. Dudley AC, Shih SC, Cliffe AR, et al. Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer 2008;99:118-25
97. Wang W, Li Q, Yamada T, et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009;15:6630-8
98. Crawford Y, Kasmam I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009;15:21-34
99. Garrido-Laguna I, Uson M, Rajeshkumar NV, et al. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 2011;17:5793-800
100. Daenen LGM, Roodhart JML, van Amersfoort M, et al. Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Res 2011;71:6976-85
101. Akiyama K, Ohga N, Hida Y, et al. Tumor endothelial cells acquire drug resistance by MDR1 Up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol 2012;180:1283-93
102. Kharaziha P, Rodriguez P, Li Q, et al. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death Dis 2012;26:3-e262
103. Hasebe T, Sasaki S, Imoto S, Ochiai A. Histological characteristics of tumors in blood vessels play an important role in tumor progression of invasive ductal carcinoma of the breast. Cancer Sci 2003;94:158-65